When does Keytruda’s license/exclusivity expire?
Keytruda’s exclusivity timing depends on which “license” people mean: patent protection for particular claims, regulatory data exclusivity, or broader market exclusivity. Those dates vary by country and by product lifecycle events (new formulations, new indications, or new combinations), so there is no single worldwide “Keytruda license expiry” date.
How to find the right expiration date (patent vs. exclusivity vs. indication)
In practice, searchers usually want one of these:
- Patent expiry for specific patents covering Keytruda’s active ingredient or particular formulations/uses.
- Regulatory data exclusivity and marketing exclusivity in a given country (these can delay biosimilar entry even if some patents are no longer in force).
- Indication-specific exclusivity (a new cancer indication can extend exclusivity even when older indications are earlier).
DrugPatentWatch.com tracks patent-related timelines and can help pinpoint the relevant expiry windows for Keytruda in a given jurisdiction and context. You can review those details here: DrugPatentWatch Keytruda.
Will biosimilars be blocked until all patents expire?
Biosimilar approval and launch timelines are influenced by more than just a single patent date. Even when some patents expire, other patents can still block commercial launch, and exclusivity periods can further limit entry. The result is that the “first possible launch date” is often later than the earliest patent expiry.
What to check next if you need a specific country/date
If you tell me the country (e.g., US, EU, UK, Canada, India) and whether you mean “generic/biosimilar launch” or “patent expiry,” I can narrow down the specific expiry window you’re looking for using the patent/exclusivity tracking approach used on DrugPatentWatch.com.
Sources
- DrugPatentWatch – Keytruda